Prognostic analysis of patients with combined hepatocellular-cholangiocarcinoma after radical resection: A retrospective multicenter cohort study

Table 1 Demographic characteristics of patients with combined hepatocellular-cholangiocarcinoma before radical resection

	Overall	The 5th Medical Center of the PLA General Hospital	Peking Union Medical College Hospital	P value
Number	98	34	64
Age, mean ± SD	55.3 (10.4)	53.5 (10.4)	56.3 (10.3)	0.219
Sex
Male	86 (87.8)	32 (88.2)	56 (87.5)	1 (Fisher)
Female (%)	12 (12.2)	4 (11.8)	8 (12.5)
ECOG (%)				0.009 (Fisher)
0	84 (85.7)	26 (76.5)	58 (90.6)
1	11 (11.2)	8 (23.5)	3 (4.7)
NA	3 (3.1)	0 (0)	3 (4.7)
Child-Pugh class				0.435 (Fisher)
A	86 (87.8)	32 (94.1)	54 (84.4)
B	6 (6.1)	1 (2.9)	5 (7.8)
NA	6 (6.1)	1 (2.9)	5 (7.8)
Liver disease (%)				0.823 (Fisher)
NA	4 (4.1)	1 (2.9)	3 (4.7)
HBV	81 (82.7)	28 (82.4)	53 (82.8)
HCV	4 (4.1)	2 (5.9)	2 (3.1)
Fatty liver	2 (2.0)	0 (0.0)	2 (3.1)
Alcohol	7 (7.1)	3 (8.8)	4 (6.2)
Gallstones (%)	13 (13.3)	3 (8.8)	10 (15.6)	0.533 (Fisher)
CA19-9 (U/mL)	26.5 [13.1, 56.2]	29.7 [15.1, 46.5]	23.6 [12.4, 56.4]	0.775 (non-norm)
< 37	58 (59.2)	21 (61.8)	37 (57.8)	0.813 (Fisher)
≥ 37	31 (31.6)	11 (32.4)	20 (31.2)
NA	9 (9.2)	2 (5.9)	7 (10.9)
AFP (ng/mL)	44.1 [7.0, 338.4]	43.4 [5.8, 294.7]	44.1 [7.8, 724.3]	0.389 (non-norm)
< 200	61 (62.2)	24 (70.6)	37 (57.8)	0.122 (Fisher)
≥ 200	30 (30.6)	10 (29.4)	20 (31.2)
NA	7 (7.1)	0 (0.0)	7 (10.9)
CEA (ng/mL)	2.7 [1.6, 4.4]	2.5 [1.5, 3.5]	2.7 [1.7, 4.8]	0.173 (non-norm)
< 6	80 (81.6)	32 (94.1)	48 (75.0)	0.038 (Fisher)
≥ 6	9 (9.2)	0 (0.0)	9 (14.1)
NA	9 (9.2)	2 (5.9)	7 (10.9)
TBil (μmol/L)	12.6 [10.4, 16.4]	12.2 [10.4, 14.0]	12.9 [10.7, 17.8]	0.260 (non-norm)
DBil (μmol/L)	4.3 [3.8, 5.7]	4.2 [3.8, 5.0]	4.5 [3.8, 5.8]	0.334 (non-norm)
Albumin (g/L)	41.0 [39.0, 43.5]	40.0 [38.0, 42.0]	41.0 [39.0, 44.0]	0.055 (non-norm)
Ascites (%)				0.094 (Fisher)
No	75 (76.5)	30 (88.2)	45 (70.3)
Yes	18 (18.4)	4 (11.8)	14 (21.9)
NA	5 (5.1)	0 (0.0)	5 (7.8)
Liver cirrhosis (%)	82 (83.7)	32 (94.1)	50 (78.1)	0.143 (Fisher)

ECOG: Eastern Cooperative Oncology Group; HBV: Hepatitis B virus; HCV: Hepatitis C virus; AFP: Alpha fetoprotein; CEA: Carcinoembryonic antigen; TBil: Total bilirubin; DBil: Direct bilirubin; NA: Not available.